CETP Inhibitor Compounds for HDL Cholesterol Elevation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacologic therapies for atherosclerosis and coronary heart disease are limited in effectively raising High Density Lipoprotein (HDL) cholesterol levels, with existing treatments like statins and fibrates offering modest gains and suffering from patient compliance issues due to side effects, and there is a need for safe and effective CETP inhibitors that can be used alone or in combination with other drugs.
Innovation Solution
Development of potent chemical compounds that inhibit Cholesteryl Ester Transfer Protein (CETP), specifically described by Formula I, which include aromatic rings, heterocyclic rings, and cycloalkyl groups, designed to raise HDL cholesterol levels and potentially lower LDL cholesterol levels, thereby improving lipid profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If existing pharmacologic therapies (statins, fibrates) are used to raise HDL cholesterol levels, then modest HDL-C gains are achieved, but patient compliance deteriorates due to side effects
Solution Approach 1:
The patent applies parameter changes by developing novel chemical compounds with specific molecular structures (Formula I) that target CETP activity. These compounds represent a fundamental change in the pharmacologic parameter of mechanism of action, moving from HMG-CoA reductase inhibition to direct CETP inhibition, thereby achieving superior HDL-C elevation without the compliance-limiting side effects of existing therapies
Solution Approach 2:
The patent employs composite materials through the design of complex molecular structures in Formula I that combine multiple functional groups (aromatic rings, heterocyclic rings, cycloalkyl groups, and various substituents). This composite molecular architecture enables potent and selective CETP inhibition, achieving effective HDL-C raising with improved safety and compliance profiles
2Reliability
If statins are used for treatment and prevention of atherosclerosis, then risk reduction of approximately one-third is achieved, but the therapeutic effect is limited and cannot sufficiently raise HDL-C levels
Solution Approach 1:
The patent applies inversion by reversing the therapeutic approach: instead of using statins that lower LDL-C with modest HDL-C benefits, the invention directly targets CETP to achieve profound HDL-C elevation. This inverted strategy addresses the unmet medical need for effective HDL-C raising, complementing or potentially replacing statin therapy for atherosclerosis prevention
Solution Approach 2:
The patent implements parameter changes by fundamentally altering the lipid profile modification approach through CETP inhibition. The compounds in Formula I produce significant HDL-C elevation and LDL-C lowering effects, representing a quantitative and qualitative change from statin therapy, thereby achieving superior cardiovascular risk reduction
3Quantity of substance
If niacin is used to raise HDL cholesterol levels, then the most effective therapy is achieved, but patient compliance deteriorates due to side effects such as flushing
Solution Approach 1:
The patent applies extraction by isolating and targeting the specific CETP enzyme responsible for HDL-C metabolism. By developing selective CETP inhibitors with Formula I structures, the invention extracts the therapeutic benefit of HDL-C elevation while eliminating the harmful flushing side effects associated with niacin, achieving effective therapy with improved tolerability
Solution Approach 2:
The patent employs an intermediary approach by introducing CETP inhibitors as a new class of compounds that mediate between the goal of HDL-C elevation and the avoidance of side effects. These compounds act as selective intermediaries that specifically inhibit CETP without activating the harmful pathways responsible for niacin-induced flushing, thereby achieving effective and compliant therapy
Data Source
AI summary
Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, A1 and A2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring.